Warfarin

Generic Name: Warfarin

Brand Names: Coumadin, Jantoven

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₁₆O_₄

CAS Number: 81-81-2

Unique Ingredient Identifier: 5Q7ZVV76EI

Background: Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication: Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions: Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)

Clinical Trials

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

Phase 3

Completed

Conditions: Atrial Fibrillation
Stroke
Embolism

Interventions: Drug: Rivaroxaban
Drug: Warfarin
Drug: Matching placebo for Rivaroxaban arm (Warfarin placebo)
Drug: Matching placebo for Warfarin arm (Rivaroxaban placebo)

First Posted Date: 2006-11-27

Last Posted Date: 2014-04-29

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 14269

Registration Number: NCT00403767

Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information

Not Applicable

Completed

Conditions: Pulmonary Embolism
Deep Vein Thrombosis
Atrial Fibrillation

Interventions: Drug: Warfarin

First Posted Date: 2006-11-20

Last Posted Date: 2013-08-30

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 344

Registration Number: NCT00401414

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Ultrasound Findings to Adjust the Duration of Anticoagulation

Phase 3

Completed

Conditions: Deep Vein Thrombosis

Interventions: Drug: Sodium warfarin

First Posted Date: 2006-09-25

Last Posted Date: 2008-03-18

Lead Sponsor: University of Padova

Target Recruit Count: 538

Registration Number: NCT00380120

Locations: 🇮🇹
Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University of Padua, Padua, Italy

PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care

Phase 4

Withdrawn

Conditions: Blood Coagulation Disorders

First Posted Date: 2006-09-15

Last Posted Date: 2012-02-16

Lead Sponsor: University of Florida

Registration Number: NCT00377143

Locations: 🇺🇸
Shands at the University of Florida, Gainesville, Florida, United States

3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE

Phase 4

Completed

Conditions: Deep Vein Thrombosis
Pulmonary Embolism
Deep Vein Thrombosis With Pulmonary Embolism

First Posted Date: 2006-08-18

Last Posted Date: 2006-08-18

Lead Sponsor: British Thoracic Society

Target Recruit Count: 2400

Registration Number: NCT00365950

Locations: 🇬🇧
Department of Chest Medicine, Llandough Hospital, Cardiff, Wales, United Kingdom
🇬🇧
Department of Chest Medicine, Llandough Hospital,, Cardiff, Wales, United Kingdom

Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach

Phase 3

Completed

Conditions: Thrombosis
Embolism

Interventions: Drug: Idrabiotaparinux sodium
Drug: Warfarin
Drug: Avidin
Drug: Placebo (for idrabiotaparinux sodium)
Drug: Placebo (for warfarin)
Drug: Enoxaparin

First Posted Date: 2006-06-28

Last Posted Date: 2016-03-21

Lead Sponsor: Sanofi

Target Recruit Count: 3202

Registration Number: NCT00345618

Locations: 🇷🇺
Sanofi-Aventis Admnistrative Office, Moscow, Russian Federation
🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
🇦🇺
sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia

and more 1 locations

Secondary Prevention of Venous Thrombo Embolism (VTE).

Phase 3

Completed

Conditions: Thromboembolism

Interventions: Drug: Dabigatran
Drug: Warfarin

First Posted Date: 2006-05-24

Last Posted Date: 2014-05-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2867

Registration Number: NCT00329238

Locations: 🇺🇸
1160.47.01030 Boehringer Ingelheim Investigational Site, Grand Forks, North Dakota, United States
🇨🇦
1160.47.02019 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada
🇲🇽
1160.47.52030 Boehringer Ingelheim Investigational Site, Guadalajara, Jal., Mexico

and more 272 locations

Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism

Phase 3

Completed

Conditions: Thromboembolism

Interventions: Drug: dabigatran etexilate 150 mg
Drug: warfarin (INR 2-3)

First Posted Date: 2006-02-14

Last Posted Date: 2014-06-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2564

Registration Number: NCT00291330

Locations: 🇺🇸
1160.53.01033 Boehringer Ingelheim Investigational Site, Sarasota, Florida, United States
🇺🇸
1160.53.01046 Boehringer Ingelheim Investigational Site, Sarasota, Florida, United States
🇺🇸
1160.53.01010 Boehringer Ingelheim Investigational Site, Marietta, Georgia, United States

and more 247 locations

Pilot Study of Aspirin Versus Warfarin for Cervicocephalic Arterial Dissection

Phase 1

Withdrawn

Conditions: Ischemic Stroke

Interventions: Drug: warfarin
Drug: aspirin

First Posted Date: 2005-12-14

Last Posted Date: 2014-12-08

Lead Sponsor: University of California, San Diego

Registration Number: NCT00265408

Locations: 🇺🇸
UCSD Medical Center, San Diego, California, United States

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

Phase 3

Completed

Conditions: Atrial Fibrillation
Stroke

Interventions: Drug: Dabigatran dose 2
Drug: Dabigatran dose 1
Drug: warfarin

First Posted Date: 2005-12-07

Last Posted Date: 2019-04-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18113

Registration Number: NCT00262600

Locations: 🇸🇪
1160.26.1633 Sahlgrenska Sjukhuset, Göteboerg, Sweden
🇺🇸
1160.26.0278 Boehringer Ingelheim Investigational Site, Bridgeport, Connecticut, United States
🇺🇸
1160.26.0358 Boehringer Ingelheim Investigational Site, Melbourne, Florida, United States

and more 981 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy